2/4
08:13 am
mtva
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel [Yahoo! Finance]
Medium
Report
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel [Yahoo! Finance]
2/4
08:00 am
mtva
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
Medium
Report
MetaVia Announces Positive AI-Modeling Results from its Ongoing Syntekabio Collaboration, Confirming Key Therapeutic Targets for Vanoglipel
1/16
04:01 pm
mtva
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
Medium
Report
MetaVia Announces the Closing of $9.3 Million Underwritten Public Offering, Including Full Exercise of Allotment Option
1/15
09:32 am
mtva
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
High
Report
MetaVia Announces the Pricing of $8.1 Million Underwritten Public Offering
1/6
01:30 pm
mtva
MetaVia (NASDAQ:MTVA) had its price target raised by analysts at HC Wainwright from $12.00 to $40.00. They now have a "buy" rating on the stock.
Low
Report
MetaVia (NASDAQ:MTVA) had its price target raised by analysts at HC Wainwright from $12.00 to $40.00. They now have a "buy" rating on the stock.
1/5
08:41 am
mtva
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile [Yaho
High
Report
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile [Yaho
1/5
08:30 am
mtva
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
Medium
Report
MetaVia Reports Positive Statistically Significant Results from Its Phase 1b Clinical Trial of DA-1726 In Metabolic Disease - Demonstrating Strong Glycemic Response, Significant Direct Hepatic Effects, Robust Weight Loss and Favorable Safety Profile
12/29
08:31 am
mtva
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
Low
Report
MetaVia to Participate in and Sponsor the 10th Annual MASH-TAG 2026 Conference
12/22
08:31 am
mtva
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
High
Report
MetaVia Regains Compliance with Nasdaq Minimum Bid Price Requirement
12/2
09:06 am
mtva
MetaVia Inc. Announces 1-for-11 Reverse Stock Split [Yahoo! Finance]
Low
Report
MetaVia Inc. Announces 1-for-11 Reverse Stock Split [Yahoo! Finance]
12/2
08:45 am
mtva
MetaVia Inc. Announces 1-for-11 Reverse Stock Split
Medium
Report
MetaVia Inc. Announces 1-for-11 Reverse Stock Split